🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A drug is finally able to improve outcomes in HFpEF! 🎉🎉 EMPEROR-Preserved phase III trial met its primary endpoint!!!! Empagliflozin demonstrated significant risk reduction for the composite of CV death or hospitalization for heart failure in adults with HFpEF

Stunning persistent gaps in the use/dosing of GDMT in HFrEF despite proven life-saving benefits driven by: No sense of urgency Will defer to outpatient/next visit/next visit Plan to initiate someday Steve Greene Muthu Vaduganathan Michelle Kittleson MD PhD Clyde Yancy, MD, MSc Javed Butler HFSA

Effective immediately, masks will be required indoors in Orleans Parish, regardless of your vaccination status. This is in order to curb the dangerous and rapid spread of the #Delta variant. When indoors with anyone who is not a member of your immediate household, wear a mask.

Highest cases/capita in the world, state or country, with population ≥ 1 million 1. Louisiana 99/100,000 2. Botswana 98/100,000 3. Florida 90/100,000

We want to keep our people safe, without shutting down again and this is the way‼️ Starting Aug 16, everyone in NOLA age 12+ MUST show proof of at least 1 dose of a #COVID vaccine or a negative PCR test within the last 72hrs to do activities with a higher risk of transmission.

The world has administered 6 billion doses of COVID vaccines to 3.4 Billion people For people waiting for more data before getting the shot The data is in We've vaccinated nearly half of all humanity The vaccines are safe

Our star resident Brennan Lanier, MD MPH highlighting the importance of dynamic stroke risk assessment at #ACC22 Nassir Marrouche Tulane Medicine Hogan Hudgins Abdel Hadi Mario Mekhael Charbel Noujaim

The many $ billions the US could save each year by Mark Cuban's Mark Cuban Cost Plus Drug Company (MCCPDC) is remarkable acpjournals.org/doi/10.7326/M2… Annals of Int Med Brigham and Women's Hospital by Hussain Lalani, MD, MPH, MSc Program On Regulation, Therapeutics, And Law Aaron Kesselheim Ben Rome

#SECURE trial: polypill containing aspirin, atorvastatin and ramipril leads to clinically relevant reductions in recurrent #cardiovascular events in post-myocardial infarction patients. #ESCCongress

#ESCCongress Let's get straight to the point about #INVICTUS The only people not surprised by the results are imagers that do TOEs (TEEs) on these patients! No way VKA was going to lose to NOACs here!😂 A 🧵... #medtwitter #cardiotwitter #echofirst #epeeps

Our superstar resident Brennan Lanier, MD MPH kicking off the second day of #ACC2023 American College of Cardiology !

Second day of #ACC2023 ! Happy to share our work. #NewOrleans American College of Cardiology TulaneTRIAD Amitabh C. Pandey Nassir Marrouche

#PARADIGM & #PARAGON “eGFR Dip” now SimPub in JACC Journals brilliantly presented by Safia Chatur, MD #ACC23 eGFR declines after #ARNI occurs in 1 in 10 & recovers in most. These dips were not prognostically meaningful & did not modify subsequent #ARNI benefits. jacc.org/doi/10.1016/j.…

The TulaneTRIAD team dominating the morning poster session at #ACC23. Nour Chouman Ala' Assaf Charbel Noujaim Hadi Younes, MD all presenting their work this morning. Great to be able to work with all of them. Nassir Marrouche Mario Mekhael Chan Ho Lim Eoin Donnellan Omar Kreidieh

We're excited to welcome an amazing class of new cardiology fellows to Cardiology Fellowship - UT Austin for July 2024!!!

Beautiful day for a run #SinusTach Lakshya Trivedi, M.D. Cardiology Fellowship - UT Austin

Extremely grateful for my mentors and program for the chance to present our findings at this year’s #ACC2024 #ACC24 Nassir Marrouche Deepa Bhatnagar Tulane Medicine Tulane Internal Medicine Tulane Department of Medicine TulaneTRIAD Han Feng Hadi Younes, MD Mayana Bsoul Ghassan Bidaoui

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today. In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days. Some thoughts on this ground breaking trial: